Advancing Toward Personalized Medicine in Lung Cancer A Focus on Gene Rearrangement Testing

2 Views

07/07/23

Presented By:
Yelina Noskina, PhD

Speaker Biography:
Yelina Noskina, Ph.D. received her doctoral degree from Rush University in Chicago, she joined Abbott Molecular, after her post-doctoral work at Northwestern University and the University of Illinois, Chicago. She has been with Abbott for over 15 years, the majority of that time has been spent focusing on Oncology at Abbott Molecular, with roles that ranged from assay support, to laboratory operations, and training. In her current role as Global Scientific Affairs Manager focusing on oncology and companion diagnostics, Yelina has been working with healthcare professionals in the research and clinical molecular diagnostic fields with the end goal of bringing about the best testing and treatment options for oncology patients.

Webinar:
Advancing Toward Personalized Medicine in Lung Cancer: A Focus on Gene Rearrangement Testing

Webinar Abstract:
Advances in genomics and molecular biomarker testing have led to tremendous improvements, ushering in a new era of personalized medicine especially in the oncology practice. Many of these biomarkers have been identified as receptor tyrosine kinases, shown to be involved in the signaling pathways associated with tumor growth and development. More interesting is that a subset of the genetic alterations observed in these biomarkers are gene rearrangements that result in constitutively activated tyrosine kinases, thus providing targets for therapies that could effectively inhibit the tyrosine kinase activity. Non-small cell lung cancer patients have benefited considerably, from these advances in targeted therapies, as there are already several therapeutics to which patients positive for specific gene rearrangements have shown remarkable response. Identifying such rearrangements is becoming part of the preliminary standard of care when diagnosing non-small cell lung cancer. Various diagnostic assays have been developed to provide such information. This webinar will review the available molecular methodologies for identifying gene rearrangements specifically focusing on ALK and ROS1 gene rearrangement testing in non-small cell lung cancer. Included in the review will be an overview of the technology, the current recommendations, common practices and challenges associated with these methodologies, to better understand the available options in order to choose the best course of action throughout the patient treatment cycle.

Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/we....binar/advancing-pers
2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/we....binar/advancing-pers
3. Click Here to get your PACE credits (Expiration date – September 8, 2022): https://www.labroots.com/credit/pace-credits/4430

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc